A cell line developed in one small lab might spark a breakthrough somewhere around the world
In a laboratory at Texas A&M, scientists have cultivated a line of canine muscle cells capable of dividing indefinitely — a small biological achievement that quietly reorders the early stages of how medicine is tested. Named Myok9, this immortalized cell line stands between the first hypothesis and the first animal, offering researchers a more patient, repeatable surface on which to ask their earliest questions. It is part of a longer human effort to make the path from idea to treatment both faster and more humane.
- Traditional muscle cells used in research exhaust themselves after only a few divisions, forcing scientists into a race against biological expiration and pulling animals into studies before the science is ready.
- Myok9 breaks that constraint — immortalized through a single introduced protein, these canine muscle cells can divide indefinitely, giving researchers a stable, reusable platform for testing therapies at the molecular level.
- The innovation arrives in step with federal pressure from the NIH to reduce animal use wherever credible alternatives exist, turning an ethical aspiration into a practical laboratory tool.
- Because the Texas A&M team is making Myok9 openly available to researchers worldwide, a cell line grown in one small lab could become standard infrastructure for muscle disease research across continents.
Inside Texas A&M's College of Veterinary Medicine and Biomedical Sciences, researchers have developed a lab-grown canine muscle cell line called Myok9 — one designed to do the early work of therapeutic testing before any living subject is involved. The problem it addresses is both simple and consequential: the primary cells traditionally used in muscle disease research are biologically authentic but short-lived, dividing only a handful of times before their usefulness ends. That fragility compresses timelines, limits thoroughness, and pulls animals into studies at a stage when researchers are still asking the most basic questions.
To overcome this, the Texas A&M team introduced a protein that allows the cells to replicate far beyond their natural limit — making them, in scientific terms, immortalized. The result is a cell line that can be tested repeatedly, refined against, and screened across multiple treatments without starting over. Results become more consistent. The early questions get answered more efficiently.
Principal investigator Dr. Peter Nghiem is careful about what Myok9 can and cannot do. It enables gene editing, gene therapy, and molecular-level evaluation — the first gate a therapy must pass. But it does not replace animal studies, which remain necessary for understanding how a treatment behaves inside a living system over time. What it does is delay that step until it is genuinely warranted.
This positions Myok9 within a broader federal initiative to reduce animal use in research wherever sound alternatives exist — not as ideology, but as practical science. Fewer animals in early-stage testing means faster development and resources concentrated where they matter most. Perhaps most significantly, the cell line is being made available to researchers globally, meaning a tool developed in one Texas laboratory could seed breakthroughs in muscle disease treatment anywhere in the world.
In a laboratory at Texas A&M's College of Veterinary Medicine and Biomedical Sciences, researchers have created something that could reshape how new therapies get tested before they ever reach an animal. The Myok9 cell line—lab-grown canine muscle cells—sits in a dish and does the work that once required living subjects. It is, in essence, a shortcut that doesn't skip the science.
The problem Myok9 solves is straightforward but consequential. When researchers want to study muscle diseases or develop new treatments, they traditionally use primary cells—muscle precursor cells taken directly from animals or people. These cells are biologically authentic, which is valuable. But they are also fragile. In laboratory conditions, they divide a few times and then stop, their lifespan exhausted. This limitation forces researchers to work fast and limits how thoroughly they can test a therapy before moving to animal studies. It also means more animals are needed earlier in the development process, when researchers are still figuring out whether a treatment even works at the molecular level.
To create Myok9, the Texas A&M team introduced a protein that allows the cells to replicate far beyond their natural limit. The cells became, in the language of the field, "immortalized." They can now divide indefinitely in the lab. This durability changes what researchers can do. They can test the same therapy repeatedly. They can refine their approach. They can screen multiple treatments in sequence without starting over with fresh cells each time. The cells also respond more consistently to experimental conditions, making results more reliable.
Dr. Peter Nghiem, the principal investigator, frames the innovation in terms of what it enables: gene editing, gene therapy, molecular-level testing—all the early questions a researcher needs to answer before committing to animal studies. "If it works, then you can move on to the next phase," he said. The next phase still involves animals. Nghiem is clear about this. No cell dish can fully replicate the complexity of a living organism, the interaction of systems, the long-term safety profile of a drug. But the cell line can answer the first set of questions faster and with fewer subjects.
This aligns with a broader federal push, particularly from the National Institutes of Health, to reduce animal use in research wherever scientifically sound alternatives exist. It is not a moral stance alone—though the ethics matter—but a practical one. Fewer animals in early-stage testing means faster development, lower costs, and resources freed for the phases where animal studies remain essential. Nghiem estimates that Myok9 can reduce animal use in the earliest stages of therapeutic evaluation, the point at which researchers are still determining whether a treatment works as intended.
What makes Myok9 potentially transformative is its accessibility. Nghiem and his team are making the cell line available to other researchers. A tool developed in one small lab can now travel. A breakthrough in muscle disease treatment might come from a lab on another continent, using cells grown in Texas. As demand for alternatives to animal testing grows—in academic research, in industry, in regulatory environments—tools like this one are expected to become standard infrastructure. The cell line represents a shift in how biomedical research balances innovation with responsibility, speed with ethics. It is not a replacement for animal studies. It is a gate that comes before the gate, a way to ask the early questions more efficiently and with less cost in living subjects.
Notable Quotes
The whole purpose is to first reduce the number of animals in research and create a model that researchers can easily access and test therapies before moving into animal studies.— Dr. Peter Nghiem, principal investigator
Animal testing is still needed to comprehensively evaluate safety and whether the therapy improves disease outcomes.— Dr. Peter Nghiem
The Hearth Conversation Another angle on the story
Why does it matter that these cells can divide indefinitely? Couldn't researchers just use fresh cells each time?
Fresh cells would work, but you'd be starting over constantly. With Myok9, you can test ten therapies in sequence on the same cell population, see how they respond, refine your approach. That consistency matters—you're not chasing variation caused by different cell batches.
So this is really about speed and efficiency, not replacing animal testing entirely.
Exactly. Animal studies aren't going away. But right now, researchers test therapies in animals to answer questions they could answer in a dish first. Myok9 lets them filter out what doesn't work before they get there.
Who benefits most from this—the researchers or the animals?
Both, but in different ways. Researchers get faster results and lower costs. Animals get used less in the early, exploratory phases when you're still figuring out basics. The real benefit is that the science doesn't slow down.
Is there a risk that having an easier cell model makes researchers lazy about moving to animal studies when they should?
That's a fair question. But the researchers I've read about seem aware of the limits. They're explicit that Myok9 answers molecular questions, not safety questions. You still need living systems for that.
How widely available is this going to be?
That's the bet Nghiem is making—that by sharing it, breakthroughs happen elsewhere. Right now it's early, but the expectation is that it becomes standard infrastructure, like other cell lines researchers access routinely.